The approach of triple helix formation in control of gene expression and the treatment of tumors expressing IGF-I

Advances in Experimental Medicine and Biology

Volumn 465, Issue , 2000, Pages 319-332

  Upegui Gonzalez, Lia C ^a   François, Jean Christophe ^b   Ly, Adama ^a   Trojan, Jerzy ^a  

^a INSERM   (France)

^b CNRS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; SOMATOMEDIN C;

CANCER; CELL PROLIFERATION; DRUG MECHANISM; GENE CONTROL; GENE EXPRESSION; GENE REPLICATION; GENE THERAPY; GENETIC TRANSCRIPTION; GLIOBLASTOMA; HUMAN; LIVER CELL CARCINOMA; NONHUMAN; PRIORITY JOURNAL; REVIEW; RNA TRANSLATION; TRIPLE HELIX;

GENE EXPRESSION REGULATION; GENE THERAPY; HUMANS; INSULIN-LIKE GROWTH FACTOR I; NEOPLASMS; NUCLEIC ACID CONFORMATION; OLIGONUCLEOTIDES, ANTISENSE;

EID: 0034481531     PISSN: 00652598     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (85)

1. Triple helix-forming oligodeoxyribonucleotides targeted to the human tumor necrosis factor (TNF) gene inhibit TNF production and block the TNF-dependent growth of human glioblastoma tumor cells
2. (A, G)-oligonucleotides form extraordinary stable triple helices with a critical R.Y sequence of the murine c-Ki-ras promoter and inhibit transcription in transfected NIH 3T3 cells
3. Human gene therapy
4. The insulin-like growth factor I receptor: A key to tumor growth?
5. Triplex DNA: Fundamentals, advances and potential applications for gene therapy
6. Anti-gene therapy: The use of ribozymes to inhibit gene function
7. Reagents for the site-specific cleavage of megabase DNA
8. Commercial prospects for gene therapy - A company survey
9. Binding of triple helix forming oligonucleotides to sites in gene promoters
10. Specific inhibition of transcription by triple helixforming oligonucleotides
11. Triplex formation inhibits HER-2/neu transcription in vitro
12. Stability of triple helices containing RNA and DNA strands: Experimental and molecular modeling studies
13. Inhibition of interferon-gamma-mediated immune functions by oligonucleotides. Suppression of human T cell proliferation by downregulation of IFN-gamma-induced ICAM-1 and Fc-receptor on accessory cells
14. Sequence-specific recognition and cleavage of duplex DNA via triple-helix formation by oligonucleotides covalently linked to a phenanthroline-copper chelate
15. Triplex DNA structures
16. Accessibility of nuclear DNA to triplex-forming oligonucleotides: The integrated HIV-1 provirus as a target
17. Progress in developments of triplex-based strategies
18. Efficient inhibition of transcription elongation in vitro by oligonucleotide phosphoramidates targeted to proviral HIV DNA
19. Progress in developping PNA as a gene-targeted drug
20. Inhibition of gene expression by triple helix directed DNA cross-linking at specific sites
21. A triple helix-forming oligonucleotide-intercalator conjugate acts as a transcriptional repressor via inhibition of NF kappa B binding to interleukin-2 receptor alpha-regulatory sequence
22. Inhibition of replication initiation by triple helixforming oligonucleotides
23. Effective tumor vaccine generated by fusion of hepatoma cells with activated B cells
24. Inhibition of Klenow fragment DNA polymerase on double-helical templates by oligonucleotide-directed triple-helix formation
25. The insulin-like growth factors: Structure and biological functions
26. Thermodynamic and conformational characterization of 5-methylcytosine-versus cytosine-substituted oligomers in DNA triple helices: Ab initio quantum mechanical and free energy perturbation studies
27. Targeted mutagenesis of simian virus 40 DNA mediated by a triple helix-forming oligonucleotide
28. Sequence-specific recognition and cleavage of double helical DNA
29. Control of oncogene expression by antisense nucleic acids
30. Sequence-specific control of gene expression by antigene and clamp oligonucleotides
31. Differential regulation of gene expression in vivo by triple helix-forming oligonucleotides as detected by a reporter enzyme
32. Prevention of tumor formation in a mouse model of Burkitt's lymphoma by 6 weeks of treatment with anti-c-myc DNA phosphorothioate
33. Gene therapy for hepatoma cells using a retrovirus vector carrying herpes simplex virus thymidine kinase gene under the control of human alpha-fetoprotein gene promoter
34. Positive and negative regulation of the erythropoietin gene
35. In vivo transcription of a progesterone-responsive gene is specifically inhibited by a triplex-forming oligonucleotide
36. Antiparallel polypurine phosphorothioate oligonucleotides form stable triplexes with the rat alpha 1(I) collagen gene promoter and inhibit transcription in cultured rat fibroblasts
37. Rat C6 glial cells synthesize insulin-like growth factor I (IGF-I) and express IGF-I receptors and IGF-II/mannose 6-phosphate receptors
38. A novel triplex-forming oligonucleotide targeted to human cyclin D, (bcl-1, proto-oncogene) promoter inhibits transcription in Hela cells
39. Inhibition of transcription of the human c-myc protooncogene by intermolecular triplex
40. Topological modification of oligonucleotides for potential inhibition of gene expression
41. Triple helix-forming oligonucleotide corresponding to the polypyrimidine sequence in the rat alpha1(I) collagen promoter specifically inhibits factor binding and transcription
42. Mechanisms of triplex-caused polymerization arrest
43. Antisense IGF-I transfer into a rat hepatoma cell line inhibits tumorigenesis by modulating MHC-I cell surface expression
44. Antitumor effect of c-myc antisense phosphorothioate oligodeoxynucleotides on human melanoma cells in vitro and and in mice
45. Inhibition of T7 RNA polymerase initiation by triple-helical DNA complexes: A model for artificial gene repression
46. Prospects for the therapeutic use of antigene oligonucleotides
47. Analysis of promoter-specific repression by triple-helical DNA complexes in a eukaryotic cell-free transcription system
48. Triplex formation by the human Ha-ras promoter inhibits Sp1 binding and in vitro transcription
49. Sequence specificity in triple-helix formation: Experimental and theoretical studies of the effect of mismatches on triplex stability
50. Human gene therapy comes of age
51. Application of transcription factor "decoy" strategy as means of gene therapy and study of gene expression in cardiovascular disease
52. Sequence-specific cleavage of double helical DNA by triple helix formation
53. Characterization of purine-motif triplex DNA-binding proteins in HeLa extracts
54. BCR/ABL oncoprotein-targeted antitumor activity of antisense oligodeoxynucleotides complementary to bcr/abl mRNA and herbimycin A, an antagonist of protein tyrosine kinase: Inhibitory effects on in vitro growth of Ph1-positive leukemia cells and BCR/ABL oncoprotein-associated transformed cells
55. Temporary ex vivo inhibition of the expression of the human oncogene HER2 (NEU) by a triple helix-forming oligonucleotide
56. Evidence that a triplex-forming oligodeoxyribonucleotide binds to the c-myc promoter in HeLa cells, thereby reducing c-myc mRNA levels
57. Suppression of insulin-like growth factor type I receptor by a triple-helix strategy, inhibits IGF-I transcription and tumorigenic potential of rat C6 glioblastoma cells
58. An RNA oligonucleotide corresponding to the polypyrimidine region of the rat alpha1(I) procollagen promoter forms a stable triplex and inhibits transcription
59. Triple-helix formation interferes with the transcription and hinged DNA structure of the interferon-inducible 6-16 gene promoter
60. Suicidal nucleotide sequences for DNA polymerization
61. Trapping DNA polymerases using triplex-forming oligodeoxyribonucleotides
62. Repair of triple helix directed psoralen adducts in human cells
63. Effect of unmodified triple helix-forming oligodeoxyribonucleotide targeted to human multidrug-resistance gene mdr1 in MDR cancer cells
64. Exclusion of RNA strands from a purine motif triple helix
65. Potential triple helix-mediated inhibition of IGF-I gene expression significantly reduces tumorigenicity of glioblastoma in an animal model
66. Relief of triple-helix-mediated promoter inhibition by elongating RNA polymerases
67. Repression of bacteriophage promoters by DNA and RNA oligonucleotides
68. Leukemia treatment in severe combined inmmnodeficiency mice by antisense oligodeoxynucleotides targeting cooperating oncogenes
69. Gene therapy: Basic concepts and recent advances
70. Regulation of androgen action by receptor gene inhibition
71. Exploiting the potential of antisense: Beyond phosphorothioate oligodeoxynucleotides
72. Site-specific cleavage of a yeast chromosome by oligonucleotide-directed triple-helix formation
73. Site-specific cleavage of human chromosome 4 mediated by triple-helix formation
74. Investigation of the intracellular stability and formation of a triple helix formed with a short purine oligonucleotide targeted to the murine c-pim-1 protooncogene promotor
75. Suppression of c-myc oncogene expression by a polyamine-complexed triplex forming oligonucleotide in MCF-7 breast cancer cells
76. Loss of tumorigenicity of rat glioblastoma directed by episome-based antisense cDNA transcription of insulin-like growth factor I
77. Presence of MHC-I and B-7 molecules in rat and human glioma cells expressing antisense IGF-I mRNA
78. Gene therapy of murine teratocarcinoma: Separate functions for insulin-like growth factors I and II in immunogenicity and differentiation
79. Treatment and prevention of rat glioblastoma by immunogenic C6 cells expressing antisense insulin-like growth factor I RNA
80. Inhibition of gene expression by triple helix formation in hepatoma cells
81. Use of the IGF-I antisense strategy in the treatment of the hepatocarcinoma
82. IGF-I antisense and triple helix treatment in hepatoma treatment
83. Triplex-directed modification of genes and gene activity
84. Targeted mutagenesis in mammalian cells mediated by intracellular triple helix formation
85. Triple helix formation inhibits transcription elongation in vitro